Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05273307 · ClinicalTrials.gov registry record · Phase 3
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
A Phase 3 study of Head and Neck Cancer and Taste Dysfunction, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05273307: Recruiting Phase 3 study of Head and Neck Cancer and Taste Dysfunction, sponsored by University of California, San Francisco.
NCT05273307 is a Phase 3 study of Head and Neck Cancer and Taste Dysfunction that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05273307, a Phase 3 study of Head and Neck Cancer and Taste Dysfunction, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and progresses throughout the course of treatment. While some symptoms such as pain, mucositis, and xerostomia can be managed with pain medications and saliva replacements, taste alteration has an earlier onset and is a more difficult symptom to readily address and intervene upon. There are no effective established interventions for taste, although this is a major issue in the patient experience. The investigator will be examining they hypothesis that a miracle fruit cube would yield the greatest benefit to improve taste dysfunction in the beginning half of radiation treatment when taste function is decreased but not absent.
Primary Outcome
The Taste Assessment is a two-item questionnaire used to determine the overall experiences of the participant taste sensation in the past 7 days; with one item asking about taste alteration and another asking about the interference of taste alteration with dietary intake. Scores for each item are obtained by responses to a Likert scale ranging from 1= "not at all" to 5="a lot", with greater scores indicating a greater taste alteration or interference.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Miraculin
- DIETARY_SUPPLEMENT Miracle Fruit Placebo Cube
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What NCT05273307 shows while recruiting
NCT05273307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Miraculin is the first listed.
NCT05273307 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05273307 about?
NCT05273307 is a clinical study titled "Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy". Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and progresses throughout the course of treatment. While some symptoms such ...
What is the current status of trial NCT05273307?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2022-03-04. Estimated completion is 2026-09-30.
What conditions does trial NCT05273307 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Taste Dysfunction.
What interventions are being tested in trial NCT05273307?
The interventions under investigation include: Miraculin (DIETARY_SUPPLEMENT), Miracle Fruit Placebo Cube (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05273307?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05273307 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05273307's enrollment target sits among peer trials
40 142nd of 250 higher than 99 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Tumescence in HNC Skin Graft Reconstruction
ACTIVE NOT RECRUITING · Phase 3
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
COMPLETED · Phase 3
-
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI